Merrick M V, Simpson J D, Ferrington C
Eur J Nucl Med. 1978 Apr 1;3(2):105-8. doi: 10.1007/BF00251633.
A new preparation of 111In DTPA for intrathecal administration has been tested and found to be a safe and highly efficacious cisternographic agent. The rate of removal of 111In DTPA from the C.S.F. and from the whole body has been measured and has been found to be of no diagnostic value in the distinction between patients with cerebral atrophy and those with normotensive hydrocephalus. Long-term retention studies show no evidence of significant long-term retention of indium in the C.S.F. The absorbed radiation dose has been investigated and found to be in good agreement with previous estimates based upon extrapolated data.
一种用于鞘内注射的新的铟 - 111二乙三胺五乙酸（¹¹¹In DTPA）制剂已通过测试，发现它是一种安全且高效的脑池造影剂。已测量了¹¹¹In DTPA从脑脊液和全身的清除率，发现其在区分脑萎缩患者和常压性脑积水患者方面没有诊断价值。长期潴留研究表明，没有证据显示铟在脑脊液中有明显的长期潴留。已对吸收辐射剂量进行了研究，发现其与基于外推数据的先前估计结果高度一致。
